Rheumatoid Arthritis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Rheumatoid Arthritis – Pipeline Review, H2 2017’, provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis

The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects

The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4D Pharma PLC

AB Science SA

AbbVie Inc

Ablynx NV

ACEA Biosciences Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amarna Therapeutics BV

Amgen Inc

Amura Holdings Ltd

Applied Genetic Technologies Corp

Aptevo Therapeutics Inc

ARA Healthcare Pvt Ltd

arGentis Pharmaceuticals LLC

Arrien Pharmaceuticals LLC

Arthrogen BV

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Atlantic Bio Sci LLC

Aurigene Discovery Technologies Ltd

Axsome Therapeutics Inc

Axxam SpA

Baliopharm AG

BCN Peptides SA

Beijing Hanmi Pharmaceutical Co Ltd

Bio-Cancer Treatment International Ltd

Biocad

Biocon Ltd

BioLingus AG

BioLite Inc

Bionovis SA

Biozeus

Bird Rock Bio Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

BTB Pharma AB

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd

Cardax Inc

Carna Biosciences Inc

CASI Pharmaceuticals Inc

CEL-SCI Corp

Celgene Corp

Cell2B Advanced Therapeutics SA

Celltrion Inc

ChemoCentryx Inc

Chipscreen Biosciences Ltd

ChironWells GmbH

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Clevexel Pharma SAS

Coherus BioSciences Inc

Commence Bio Inc

Compugen Ltd

Crossject SA

CSL Ltd

Cyclacel Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Diamyd Medical AB

Domainex Ltd

Dr. Reddy's Laboratories Ltd

Eisai Co Ltd

Eli Lilly and Co

Enceladus Pharmaceuticals BV

Endocyte Inc

Enzene Biosciences Ltd

F. Hoffmann-La Roche Ltd

Fountain Biopharma Inc

Fresenius SE & Co KGaA

Fujifilm Holdings Corporation

Galapagos NV

Gene Techno Science Co Ltd

Genentech Inc

Genfit SA

Genor BioPharma Co Ltd

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Griffin Discoveries BV

Han Wha Pharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Hansa Medical AB

Hanwha Chemical Corp

Hetero Drugs Ltd

HitGen LTD

Huabo Biopharm Co Ltd

Hutchison MediPharma Ltd

Idogen AB

Immune Response BioPharma Inc

Immungenetics AG

ImmunoFrontier Inc

Immunwork Inc

Innate Pharma SA

Innovent Biologics Inc

Intas Pharmaceuticals Ltd

Istesso Ltd

Japan Tobacco Inc

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jyant Technologies Inc

Kadmon Corp LLC

KAHR medical Ltd

Kang Stem Biotech Co Ltd

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Lead Pharma Holding BV

LG Chem Ltd

Lipocure Ltd

Livzon Pharmaceutical Group Inc

LSK BioPartners Inc

Lupin Ltd

Mabion SA

mAbxience SA

MacroGenics Inc

Maruho Co Ltd

Mebiopharm Co Ltd

MedAnnex Ltd

Medestea Research & Production SpA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mesoblast Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

ModiQuest Group

Momenta Pharmaceuticals Inc

Morphotek Inc

Mycenax Biotech Inc

MYOS RENS Technology Inc

Myungmoon pharmaceutical Co Ltd

Navigen Inc

Nichi-Iko Pharmaceutical Co Ltd

Nissan Chemical Industries Ltd

Novartis AG

NovelMed Therapeutics Inc

NovImmune SA

Nuevolution AB

Numab Innovation AG

Omeros Corp

Oncobiologics Inc

Oncodesign SA

OncoImmune Inc

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Paras Biopharmaceuticals Finland Oy

Peptinov SAS

Pfenex Inc

Pfizer Inc

Pharmacyclics Inc

Pharmascience Inc

Pharmedartis GmbH

Philogen SpA

PlantForm Corp

PLx Pharma Inc

Principia Biopharma Inc

ProNoxis AB

Protab Ltd

Protalex Inc

Protalix BioTherapeutics Inc

Qilu Pharmaceutical Co Ltd

Qu Biologics Inc

R Pharm

ReceptoPharm Inc

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Resverlogix Corp

ReveraGen BioPharma Inc

Rhizen Pharmaceuticals SA

Ribomic Inc

Richter Gedeon Nyrt

Rottapharm Biotech Srl

Saje Pharma LLC

Sandoz International GmbH

Sareum Holdings Plc

SBI Biotech Co Ltd

Selecta Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Synermore Biologics Co Ltd

Synovo GmbH

Takeda Pharmaceutical Co Ltd

Teijin Pharma Ltd

TheraMAB LLC

Tiziana Life Sciences Plc

Toleranzia AB

TTY Biopharm Company Ltd

Tumorend LLC

Twoxar Inc

TxCell SA

U.S. Stem Cell Inc

UCB SA

United BioPharma Inc

Vaccinex Inc

Valeant Pharmaceuticals International Inc

Vicore Pharma AB

viDA Therapeutics Inc

Xbrane Biopharma AB

Xencor Inc

XL-protein GmbH

Yungjin Pharm Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Rheumatoid Arthritis - Overview 11

Rheumatoid Arthritis - Therapeutics Development 12

Rheumatoid Arthritis - Therapeutics Assessment 61

Rheumatoid Arthritis - Companies Involved in Therapeutics Development 83

Rheumatoid Arthritis - Drug Profiles 178

Rheumatoid Arthritis - Dormant Projects 940

Rheumatoid Arthritis - Discontinued Products 971

Rheumatoid Arthritis - Product Development Milestones 978

Appendix 1003

List of Tables

List of Tables

Number of Products under Development for Rheumatoid Arthritis, H2 2017 59

Number of Products under Development by Companies, H2 2017 61

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 62

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 63

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 64

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 65

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 66

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 67

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 68

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 69

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 70

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 71

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 72

Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 73

Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 74

Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017 75

Number of Products under Development by Universities/Institutes, H2 2017 76

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 78

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 79

Products under Development by Companies, H2 2017 80

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 81

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 82

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 83

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 84

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 85

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 86

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 87

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 88

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 89

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 90

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 91

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 92

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 93

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 94

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 95

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 96

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 97

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 98

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 99

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 100

Products under Development by Companies, H2 2017 (Contd..21), H2 2017 101

Products under Development by Companies, H2 2017 (Contd..22), H2 2017 102

Products under Development by Companies, H2 2017 (Contd..23), H2 2017 103

Products under Development by Companies, H2 2017 (Contd..24), H2 2017 104

Products under Development by Universities/Institutes, H2 2017 105

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 106

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 107

Number of Products by Stage and Target, H2 2017 109

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 110

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 111

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 112

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 113

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 114

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 115

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 116

Number of Products by Stage and Mechanism of Action, H2 2017 118

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 119

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 120

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 121

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 122

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 123

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 124

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 125

Number of Products by Stage and Route of Administration, H2 2017 127

Number of Products by Stage and Molecule Type, H2 2017 129

Rheumatoid Arthritis – Pipeline by 3SBio Inc, H2 2017 130

Rheumatoid Arthritis – Pipeline by 4D Pharma PLC, H2 2017 130

Rheumatoid Arthritis – Pipeline by AB Science SA, H2 2017 131

Rheumatoid Arthritis – Pipeline by AbbVie Inc, H2 2017 132

Rheumatoid Arthritis – Pipeline by Ablynx NV, H2 2017 132

Rheumatoid Arthritis – Pipeline by ACEA Biosciences Inc, H2 2017 133

Rheumatoid Arthritis – Pipeline by Aclaris Therapeutics Inc, H2 2017 133

Rheumatoid Arthritis – Pipeline by Adello Biologics LLC, H2 2017 133

Rheumatoid Arthritis – Pipeline by Allergan Plc, H2 2017 134

Rheumatoid Arthritis – Pipeline by Alteogen Inc, H2 2017 134

Rheumatoid Arthritis – Pipeline by Amarna Therapeutics BV, H2 2017 134

Rheumatoid Arthritis – Pipeline by Amgen Inc, H2 2017 135

Rheumatoid Arthritis – Pipeline by Amura Holdings Ltd, H2 2017 135

Rheumatoid Arthritis – Pipeline by Applied Genetic Technologies Corp, H2 2017 136

Rheumatoid Arthritis – Pipeline by Aptevo Therapeutics Inc, H2 2017 137

Rheumatoid Arthritis – Pipeline by ARA Healthcare Pvt Ltd, H2 2017 137

Rheumatoid Arthritis – Pipeline by arGentis Pharmaceuticals LLC, H2 2017 138

Rheumatoid Arthritis – Pipeline by Arrien Pharmaceuticals LLC, H2 2017 138

Rheumatoid Arthritis – Pipeline by Arthrogen BV, H2 2017 139

Rheumatoid Arthritis – Pipeline by Asahi Kasei Pharma Corp, H2 2017 139

Rheumatoid Arthritis – Pipeline by Astellas Pharma Inc, H2 2017 140

Rheumatoid Arthritis – Pipeline by AstraZeneca Plc, H2 2017 140

Rheumatoid Arthritis – Pipeline by Atlantic Bio Sci LLC, H2 2017 141

Rheumatoid Arthritis – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 141

Rheumatoid Arthritis – Pipeline by Axsome Therapeutics Inc, H2 2017 142

Rheumatoid Arthritis – Pipeline by Axxam SpA, H2 2017 142

Rheumatoid Arthritis – Pipeline by Baliopharm AG, H2 2017 142

Rheumatoid Arthritis – Pipeline by BCN Peptides SA, H2 2017 143

Rheumatoid Arthritis – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017 143

Rheumatoid Arthritis – Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 144

Rheumatoid Arthritis – Pipeline by Biocad, H2 2017 144

Rheumatoid Arthritis – Pipeline by Biocon Ltd, H2 2017 145

Rheumatoid Arthritis – Pipeline by BioLingus AG, H2 2017 145

Rheumatoid Arthritis – Pipeline by BioLite Inc, H2 2017 145

Rheumatoid Arthritis – Pipeline by Bionovis SA, H2 2017 146

Rheumatoid Arthritis – Pipeline by Biozeus, H2 2017 146

Rheumatoid Arthritis – Pipeline by Bird Rock Bio Inc, H2 2017 146

Rheumatoid Arthritis – Pipeline by Boehringer Ingelheim GmbH, H2 2017 147

Rheumatoid Arthritis – Pipeline by Bristol-Myers Squibb Co, H2 2017 148

Rheumatoid Arthritis – Pipeline by BTB Pharma AB, H2 2017 148

Rheumatoid Arthritis – Pipeline by Cadila Healthcare Ltd, H2 2017 149

Rheumatoid Arthritis – Pipeline by Can-Fite BioPharma Ltd, H2 2017 149

Rheumatoid Arthritis – Pipeline by Cardax Inc, H2 2017 150

Rheumatoid Arthritis – Pipeline by Carna Biosciences Inc, H2 2017 150

Rheumatoid Arthritis – Pipeline by CASI Pharmaceuticals Inc, H2 2017 151

Rheumatoid Arthritis – Pipeline by CEL-SCI Corp, H2 2017 151

Rheumatoid Arthritis – Pipeline by Celgene Corp, H2 2017 152

Rheumatoid Arthritis – Pipeline by Cell2B Advanced Therapeutics SA, H2 2017 152

Rheumatoid Arthritis – Pipeline by Celltrion Inc, H2 2017 153

Rheumatoid Arthritis – Pipeline by ChemoCentryx Inc, H2 2017 153

Rheumatoid Arthritis – Pipeline by Chipscreen Biosciences Ltd, H2 2017 154

Rheumatoid Arthritis – Pipeline by ChironWells GmbH, H2 2017 154

Rheumatoid Arthritis – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 154

Rheumatoid Arthritis – Pipeline by CJ HealthCare Corp, H2 2017 155

Rheumatoid Arthritis – Pipeline by Clevexel Pharma SAS, H2 2017 155

Rheumatoid Arthritis – Pipeline by Coherus BioSciences Inc, H2 2017 156

Rheumatoid Arthritis – Pipeline by Commence Bio Inc, H2 2017 156

Rheumatoid Arthritis – Pipeline by Compugen Ltd, H2 2017 157

Rheumatoid Arthritis – Pipeline by Crossject SA, H2 2017 157

Rheumatoid Arthritis – Pipeline by CSL Ltd, H2 2017 158

Rheumatoid Arthritis – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 158

Rheumatoid Arthritis – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 159

Rheumatoid Arthritis – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 159

Rheumatoid Arthritis – Pipeline by Diamyd Medical AB, H2 2017 160

Rheumatoid Arthritis – Pipeline by Domainex Ltd, H2 2017 160

Rheumatoid Arthritis – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 161

Rheumatoid Arthritis – Pipeline by Eisai Co Ltd, H2 2017 161

Rheumatoid Arthritis – Pipeline by Eli Lilly and Co, H2 2017 162

Rheumatoid Arthritis – Pipeline by Enceladus Pharmaceuticals BV, H2 2017 162

Rheumatoid Arthritis – Pipeline by Endocyte Inc, H2 2017 162

Rheumatoid Arthritis – Pipeline by Enzene Biosciences Ltd, H2 2017 163

Rheumatoid Arthritis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 163

Rheumatoid Arthritis – Pipeline by Fountain Biopharma Inc, H2 2017 164

Rheumatoid Arthritis – Pipeline by Fresenius SE & Co KGaA, H2 2017 164

Rheumatoid Arthritis – Pipeline by Fujifilm Holdings Corporation, H2 2017 165

Rheumatoid Arthritis – Pipeline by Galapagos NV, H2 2017 165

Rheumatoid Arthritis – Pipeline by Gene Techno Science Co Ltd, H2 2017 166

Rheumatoid Arthritis – Pipeline by Genentech Inc, H2 2017 166

Rheumatoid Arthritis – Pipeline by Genfit SA, H2 2017 167

Rheumatoid Arthritis – Pipeline by Genor BioPharma Co Ltd, H2 2017 167

Rheumatoid Arthritis – Pipeline by Genosco Inc, H2 2017 167

Rheumatoid Arthritis – Pipeline by Gilead Sciences Inc, H2 2017 168

Rheumatoid Arthritis – Pipeline by GlaxoSmithKline Plc, H2 2017 169

Rheumatoid Arthritis – Pipeline by Griffin Discoveries BV, H2 2017 169

Rheumatoid Arthritis – Pipeline by Han Wha Pharma Co Ltd, H2 2017 169

Rheumatoid Arthritis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 170

Rheumatoid Arthritis – Pipeline by Hansa Medical AB, H2 2017 170

Rheumatoid Arthritis – Pipeline by Hanwha Chemical Corp, H2 2017 171

Rheumatoid Arthritis – Pipeline by Hetero Drugs Ltd, H2 2017 171

Rheumatoid Arthritis – Pipeline by HitGen LTD, H2 2017 172

Rheumatoid Arthritis – Pipeline by Huabo Biopharm Co Ltd, H2 2017 172

Rheumatoid Arthritis – Pipeline by Hutchison MediPharma Ltd, H2 2017 172

Rheumatoid Arthritis – Pipeline by Idogen AB, H2 2017 173

Rheumatoid Arthritis – Pipeline by Immune Response BioPharma Inc, H2 2017 173

Rheumatoid Arthritis – Pipeline by Immungenetics AG, H2 2017 174

Rheumatoid Arthritis – Pipeline by ImmunoFrontier Inc, H2 2017 174

Rheumatoid Arthritis – Pipeline by Immunwork Inc, H2 2017 174

Rheumatoid Arthritis – Pipeline by Innate Pharma SA, H2 2017 175

Rheumatoid Arthritis – Pipeline by Innovent Biologics Inc, H2 2017 175

Rheumatoid Arthritis – Pipeline by Intas Pharmaceuticals Ltd, H2 2017 176

Rheumatoid Arthritis – Pipeline by Istesso Ltd, H2 2017 176

Rheumatoid Arthritis – Pipeline by Japan Tobacco Inc, H2 2017 176

Rheumatoid Arthritis – Pipeline by JHL Biotech Inc, H2 2017 177

Rheumatoid Arthritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 177

Rheumatoid Arthritis – Pipeline by Johnson & Johnson, H2 2017 178

Rheumatoid Arthritis – Pipeline by Jyant Technologies Inc, H2 2017 179

Rheumatoid Arthritis – Pipeline by Kadmon Corp LLC, H2 2017 179

Rheumatoid Arthritis – Pipeline by KAHR medical Ltd, H2 2017 179

Rheumatoid Arthritis – Pipeline by Kang Stem Biotech Co Ltd, H2 2017 180

Rheumatoid Arthritis – Pipeline by Karyopharm Therapeutics Inc, H2 2017 180

Rheumatoid Arthritis – Pipeline by KPI Therapeutics Inc, H2 2017 180

Rheumatoid Arthritis – Pipeline by Lead Pharma Holding BV, H2 2017 181

Rheumatoid Arthritis – Pipeline by LG Chem Ltd, H2 2017 181

Rheumatoid Arthritis – Pipeline by Lipocure Ltd, H2 2017 182

Rheumatoid Arthritis – Pipeline by Livzon Pharmaceutical Group Inc, H2 2017 182

Rheumatoid Arthritis – Pipeline by LSK BioPartners Inc, H2 2017 183

Rheumatoid Arthritis – Pipeline by Lupin Ltd, H2 2017 183

Rheumatoid Arthritis – Pipeline by Mabion SA, H2 2017 184

Rheumatoid Arthritis – Pipeline by mAbxience SA, H2 2017 184

Rheumatoid Arthritis – Pipeline by MacroGenics Inc, H2 2017 185

Rheumatoid Arthritis – Pipeline by Maruho Co Ltd, H2 2017 185

Rheumatoid Arthritis – Pipeline by Mebiopharm Co Ltd, H2 2017 186

Rheumatoid Arthritis – Pipeline by MedAnnex Ltd, H2 2017 186

Rheumatoid Arthritis – Pipeline by Medestea Research & Production SpA, H2 2017 186

Rheumatoid Arthritis – Pipeline by MedImmune LLC, H2 2017 187

Rheumatoid Arthritis – Pipeline by Merck & Co Inc, H2 2017 187

Rheumatoid Arthritis – Pipeline by Merck KGaA, H2 2017 188

Rheumatoid Arthritis – Pipeline by Mesoblast Ltd, H2 2017 188

Rheumatoid Arthritis – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 189

Rheumatoid Arthritis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 189

Rheumatoid Arthritis – Pipeline by ModiQuest Group, H2 2017 190

Rheumatoid Arthritis – Pipeline by Momenta Pharmaceuticals Inc, H2 2017 190

Rheumatoid Arthritis – Pipeline by Morphotek Inc, H2 2017 191

Rheumatoid Arthritis – Pipeline by Mycenax Biotech Inc, H2 2017 191

Rheumatoid Arthritis – Pipeline by MYOS RENS Technology Inc, H2 2017 192

Rheumatoid Arthritis – Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2017 192

Rheumatoid Arthritis – Pipeline by Navigen Inc, H2 2017 193

Rheumatoid Arthritis – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017 193

Rheumatoid Arthritis – Pipeline by Nissan Chemical Industries Ltd, H2 2017 194

Rheumatoid Arthritis – Pipeline by Novartis AG, H2 2017 194

Rheumatoid Arthritis – Pipeline by NovelMed Therapeutics Inc, H2 2017 195

Rheumatoid Arthritis – Pipeline by NovImmune SA, H2 2017 195

Rheumatoid Arthritis – Pipeline by Nuevolution AB, H2 2017 195

Rheumatoid Arthritis – Pipeline by Numab Innovation AG, H2 2017 196

Rheumatoid Arthritis – Pipeline by Omeros Corp, H2 2017 196

Rheumatoid Arthritis – Pipeline by Oncobiologics Inc, H2 2017 197

Rheumatoid Arthritis – Pipeline by Oncodesign SA, H2 2017 197

Rheumatoid Arthritis – Pipeline by OncoImmune Inc, H2 2017 198

Rheumatoid Arthritis – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 198

Rheumatoid Arthritis – Pipeline by OSE Immunotherapeutics, H2 2017 199

Rheumatoid Arthritis – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017 199

Rheumatoid Arthritis – Pipeline by Peptinov SAS, H2 2017 199

Rheumatoid Arthritis – Pipeline by Pfenex Inc, H2 2017 200

Rheumatoid Arthritis – Pipeline by Pfizer Inc, H2 2017 201

Rheumatoid Arthritis – Pipeline by Pharmacyclics Inc, H2 2017 201

Rheumatoid Arthritis – Pipeline by Pharmascience Inc, H2 2017 202

Rheumatoid Arthritis – Pipeline by Pharmedartis GmbH, H2 2017 202

Rheumatoid Arthritis – Pipeline by Philogen SpA, H2 2017 202

Rheumatoid Arthritis – Pipeline by PlantForm Corp, H2 2017 203

Rheumatoid Arthritis – Pipeline by PLx Pharma Inc, H2 2017 203

Rheumatoid Arthritis – Pipeline by Principia Biopharma Inc, H2 2017 203

Rheumatoid Arthritis – Pipeline by ProNoxis AB, H2 2017 204

Rheumatoid Arthritis – Pipeline by Protab Ltd, H2 2017 204

Rheumatoid Arthritis – Pipeline by Protalex Inc, H2 2017 205

Rheumatoid Arthritis – Pipeline by Protalix BioTherapeutics Inc, H2 2017 205

Rheumatoid Arthritis – Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017 205

Rheumatoid Arthritis – Pipeline by Qu Biologics Inc, H2 2017 206

Rheumatoid Arthritis – Pipeline by R Pharm, H2 2017 206

Rheumatoid Arthritis – Pipeline by ReceptoPharm Inc, H2 2017 207

Rheumatoid Arthritis – Pipeline by RedHill Biopharma Ltd, H2 2017 207

Rheumatoid Arthritis – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 208

Rheumatoid Arthritis – Pipeline by Resverlogix Corp, H2 2017 208

Rheumatoid Arthritis – Pipeline by ReveraGen BioPharma Inc, H2 2017 208

Rheumatoid Arthritis – Pipeline by Rhizen Pharmaceuticals SA, H2 2017 209

Rheumatoid Arthritis – Pipeline by Ribomic Inc, H2 2017 209

Rheumatoid Arthritis – Pipeline by Richter Gedeon Nyrt, H2 2017 210

Rheumatoid Arthritis – Pipeline by Rottapharm Biotech Srl, H2 2017 210

Rheumatoid Arthritis – Pipeline by Saje Pharma LLC, H2 2017 210

Rheumatoid Arthritis – Pipeline by Sandoz International GmbH, H2 2017 211

Rheumatoid Arthritis – Pipeline by Sareum Holdings Plc, H2 2017 211

Rheumatoid Arthritis – Pipeline by SBI Biotech Co Ltd, H2 2017 212

Rheumatoid Arthritis – Pipeline by Selecta Biosciences Inc, H2 2017 212

Rheumatoid Arthritis – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017 213

Rheumatoid Arthritis – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017 213

Rheumatoid Arthritis – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H2 2017 214

Rheumatoid Arthritis – Pipeline by Synermore Biologics Co Ltd, H2 2017 214

Rheumatoid Arthritis – Pipeline by Synovo GmbH, H2 2017 214

Rheumatoid Arthritis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 215

Rheumatoid Arthritis – Pipeline by Teijin Pharma Ltd, H2 2017 215

Rheumatoid Arthritis – Pipeline by TheraMAB LLC, H2 2017 216

Rheumatoid Arthritis – Pipeline by Tiziana Life Sciences Plc, H2 2017 216

Rheumatoid Arthritis – Pipeline by Toleranzia AB, H2 2017 217

Rheumatoid Arthritis – Pipeline by TTY Biopharm Company Ltd, H2 2017 217

Rheumatoid Arthritis – Pipeline by Tumorend LLC, H2 2017 217

Rheumatoid Arthritis – Pipeline by Twoxar Inc, H2 2017 218

Rheumatoid Arthritis – Pipeline by TxCell SA, H2 2017 218

Rheumatoid Arthritis – Pipeline by U.S. Stem Cell Inc, H2 2017 219

Rheumatoid Arthritis – Pipeline by UCB SA, H2 2017 219

Rheumatoid Arthritis – Pipeline by United BioPharma Inc, H2 2017 219

Rheumatoid Arthritis – Pipeline by Vaccinex Inc, H2 2017 220

Rheumatoid Arthritis – Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 220

Rheumatoid Arthritis – Pipeline by Vicore Pharma AB, H2 2017 221

Rheumatoid Arthritis – Pipeline by viDA Therapeutics Inc, H2 2017 221

Rheumatoid Arthritis – Pipeline by Xbrane Biopharma AB, H2 2017 222

Rheumatoid Arthritis – Pipeline by Xencor Inc, H2 2017 222

Rheumatoid Arthritis – Pipeline by XL-protein GmbH, H2 2017 222

Rheumatoid Arthritis – Pipeline by Yungjin Pharm Co Ltd, H2 2017 223

Rheumatoid Arthritis – Pipeline by Yuyu Pharma Inc, H2 2017 224

Rheumatoid Arthritis – Dormant Projects, H2 2017 987

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..1), H2 2017 988

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..2), H2 2017 989

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..3), H2 2017 990

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..4), H2 2017 991

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..5), H2 2017 992

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..6), H2 2017 993

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..7), H2 2017 994

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..8), H2 2017 995

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..9), H2 2017 996

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..10), H2 2017 997

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..11), H2 2017 998

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..12), H2 2017 999

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..13), H2 2017 1000

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..14), H2 2017 1001

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..15), H2 2017 1002

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..16), H2 2017 1003

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..17), H2 2017 1004

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..18), H2 2017 1005

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..19), H2 2017 1006

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..20), H2 2017 1007

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..21), H2 2017 1008

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..22), H2 2017 1009

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..23), H2 2017 1010

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..24), H2 2017 1011

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..25), H2 2017 1013

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..26), H2 2017 1014

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..27), H2 2017 1015

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..28), H2 2017 1016

Rheumatoid Arthritis – Dormant Projects, H2 2017 (Contd..29), H2 2017 1017

Rheumatoid Arthritis – Discontinued Products, H2 2017 1018

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..1), H2 2017 1019

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..2), H2 2017 1020

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..3), H2 2017 1021

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..4), H2 2017 1022

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..5), H2 2017 1023

Rheumatoid Arthritis – Discontinued Products, H2 2017 (Contd..6), H2 2017 1024

List of Figures

List of Figures

Number of Products under Development for Rheumatoid Arthritis, H2 2017 59

Number of Products under Development by Companies, H2 2017 60

Number of Products under Development by Universities/Institutes, H2 2017 76

Number of Products by Top 10 Targets, H2 2017 108

Number of Products by Stage and Top 10 Targets, H2 2017 108

Number of Products by Top 10 Mechanism of Actions, H2 2017 117

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 117

Number of Products by Routes of Administration, H2 2017 126

Number of Products by Stage and Routes of Administration, H2 2017 126

Number of Products by Top 10 Molecule Types, H2 2017 128

Number of Products by Stage and Top 10 Molecule Types, H2 2017 128

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports